137 related articles for article (PubMed ID: 35368772)
1. Association between NF-
Shen X; Tan S; Feng X; Fu W; Hu Y; Li M; Wang W; Yuan H; Liu L; Wang C; Hua F
Evid Based Complement Alternat Med; 2022; 2022():2461716. PubMed ID: 35368772
[TBL] [Abstract][Full Text] [Related]
2. Genetic Polymorphisms of Nuclear Factor-κB Family Affect the Bone Mineral Density Response to Zoledronic Acid Therapy in Postmenopausal Chinese Women.
Wang WJ; He JW; Fu WZ; Wang C; Zhang ZL
Genes (Basel); 2022 Jul; 13(8):. PubMed ID: 36011257
[TBL] [Abstract][Full Text] [Related]
3. Association Between
Yuan H; Wang C; Liu L; Wang C; Zhang Z; Qu S
Pharmgenomics Pers Med; 2023; 16():925-932. PubMed ID: 37920752
[TBL] [Abstract][Full Text] [Related]
4. OPG, RANKL, and RANK gene polymorphisms and the bone mineral density response to alendronate therapy in postmenopausal Chinese women with osteoporosis or osteopenia.
Zheng H; Wang C; He JW; Fu WZ; Zhang ZL
Pharmacogenet Genomics; 2016 Jan; 26(1):12-9. PubMed ID: 26426211
[TBL] [Abstract][Full Text] [Related]
5. Association between SOST gene polymorphisms and response to alendronate treatment in postmenopausal Chinese women with low bone mineral density.
Wang WJ; Fu WZ; He JW; Wang C; Zhang ZL
Pharmacogenomics J; 2019 Oct; 19(5):490-498. PubMed ID: 30287911
[TBL] [Abstract][Full Text] [Related]
6. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
7.
Zhao J; Liu L; Lv S; Wang C; Yue H; Zhang Z
Pharmgenomics Pers Med; 2021; 14():1669-1678. PubMed ID: 34992429
[TBL] [Abstract][Full Text] [Related]
8. Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(20):1-180. PubMed ID: 23074491
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and tolerability of once-weekly alendronate 70 mg on bone mineral density and bone turnover markers in postmenopausal Chinese women with osteoporosis.
Yan Y; Wang W; Zhu H; Li M; Liu J; Luo B; Xie H; Zhang G; Li F
J Bone Miner Metab; 2009; 27(4):471-8. PubMed ID: 19343272
[TBL] [Abstract][Full Text] [Related]
10. Influence of type 2 diabetes mellitus on bone mineral density response to bisphosphonates in late postmenopausal osteoporosis.
Dagdelen S; Sener D; Bayraktar M
Adv Ther; 2007; 24(6):1314-20. PubMed ID: 18165214
[TBL] [Abstract][Full Text] [Related]
11. [The efficacy of alendronate in the prevention and treatment of postmenopausal osteoporosis].
Cheng ZQ; Yin W; Fan JY; Ma TJ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2002 Jun; 24(3):306-9. PubMed ID: 12905641
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
[TBL] [Abstract][Full Text] [Related]
13. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
Bonnick S; Broy S; Kaiser F; Teutsch C; Rosenberg E; DeLucca P; Melton M
Curr Med Res Opin; 2007 Jun; 23(6):1341-9. PubMed ID: 17594775
[TBL] [Abstract][Full Text] [Related]
14. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
McComsey GA; Kendall MA; Tebas P; Swindells S; Hogg E; Alston-Smith B; Suckow C; Gopalakrishnan G; Benson C; Wohl DA
AIDS; 2007 Nov; 21(18):2473-82. PubMed ID: 18025884
[TBL] [Abstract][Full Text] [Related]
15. [Alendronate in postmenopausal women with osteopenia and osteoporosis: effects on bone mineral density during treatment and after withdrawal].
Jiang Y; Li M; Xia W; Xing X; Yu W; Tian J; Meng X; Zhou X
Zhonghua Yi Xue Za Zhi; 2002 Sep; 82(18):1254-6. PubMed ID: 12425805
[TBL] [Abstract][Full Text] [Related]
16. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis.
Devogelaer JP; Broll H; Correa-Rotter R; Cumming DC; De Deuxchaisnes CN; Geusens P; Hosking D; Jaeger P; Kaufman JM; Leite M; Leon J; Liberman U; Menkes CJ; Meunier PJ; Reid I; Rodriguez J; Romanowicz A; Seeman E; Vermeulen A; Hirsch LJ; Lombardi A; Plezia K; Santora AC; Yates AJ; Yuan W
Bone; 1996 Feb; 18(2):141-50. PubMed ID: 8833208
[TBL] [Abstract][Full Text] [Related]
17. Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.
Dobnig H; Hofbauer LC; Viereck V; Obermayer-Pietsch B; Fahrleitner-Pammer A
Osteoporos Int; 2006; 17(5):693-703. PubMed ID: 16435076
[TBL] [Abstract][Full Text] [Related]
18. Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis.
Tan W; Sun J; Zhou L; Li Y; Wu X
J Clin Pharm Ther; 2016 Oct; 41(5):519-23. PubMed ID: 27440710
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonates for prevention of postmenopausal osteoporosis.
Ravn P
Dan Med Bull; 2002 Feb; 49(1):1-18. PubMed ID: 11894721
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study.
Paggiosi MA; Peel N; McCloskey E; Walsh JS; Eastell R
Osteoporos Int; 2014 Dec; 25(12):2729-41. PubMed ID: 25074351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
